MedTrace Logo

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis

NCT04631016 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 137

Last updated 2025-02-27

Study results available
· View outcomes & findings →

Summary

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult participants with Chronic Obstructive Pulmonary Disease and Chronic Bronchitis.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)
  • Chronic Bronchitis

Interventions

DRUG

Tozorakimab

Participants will receive SC injection of tozorakimab as stated in arm description.

OTHER

Placebo

Participants will receive SC injection of placebo as stated in arm description.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2023-05-30
Completion
2023-11-13
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Czechia
  • Denmark
  • Germany
  • Hungary
  • Israel
  • Netherlands
  • New Zealand
  • Poland
  • South Africa
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04631016 on ClinicalTrials.gov